According
to the results of a Phase II clinical trial, the addition of the
targeted therapy Nexavar® (sorafenib) to chemotherapy may delay the
progression of advanced breast cancer. These results were presented at
a European cancer conference.
Targeted therapies are anticancer
drugs that interfere with specific pathways involved in cancer cell
growth or survival. Some targeted therapies block growth signals from
reaching cancer cells; others reduce the blood supply to cancer cells;
and still others stimulate the immune system to recognize and attack
the cancer cell. Depending on the specific “target,” targeted therapies
may slow cancer cell growth or increase cancer cell death.
Nexavar
is a targeted therapy that has been approved for use in selected
patients with liver cancer or kidney cancer. To explore the potential
role of Nexavar in the treatment of breast cancer, researchers
conducted a Phase II clinical trial among 229 women with locally
advanced or metastatic, HER2-negative breast cancer.
The study was restricted to women who had received no more than one
prior chemotherapy regimen for advanced/metastatic breast cancer.
Half the women were given chemotherapy with Xeloda® (capecitabine) alone and half the women were given Xeloda plus Nexavar.
On
average, women who received Xeloda plus Nexavar survived longer without
cancer progression than women who received Xeloda alone.
Progression-free survival was 6.4 months among women treated with
Xeloda plus Nexavar compared with 4.1 months among women treated with
Xeloda alone.
Information about overall survival is not yet available.
13.4%
of women treated with Xeloda plus Nexavar discontinued treatment due to
side effects compared with 8% of women treated with Xeloda alone.
Though
still not approved for use in breast cancer, the results of this study
suggest that the addition of Nexavar to chemotherapy may delay cancer
progression among women with advanced breast cancer.
Reference: Baselga J, Seqalla JGM, Roche H et al. SOLTI-0701:
A double-blind, randomized phase 2b study evaluating the efficacy and
safety of sorafenib (SOR) compared to placebo (PL) when administered in
combination with capecitabine (CAP) in patients (pts) with locally
advanced (adv) or metastatic (met) breast cancer (BC). Presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress. Berlin, Germany, September 20-24, 2009. Abstract 3LBA.
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09) 11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15
Thanks Donna. It is a good day today. Science is back! I just saw the Obama presser announcing the billions being released for medical research as part of the incentive package today. Hope is a grand thing.
I ascribe to this philosophy...because without hope what would motivate us to discover new things....always hoping to improve ourselves, or the world we live in.
"Things never go so well that one should have no fear, and never so ill that one should have no hope."~ Turkish Proverb
With October being Breast Cancer Awareness month in the states, I hope we see more positive scientific news releases about this disease. Hope is a good thing, it keeps us pushing forward!
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09) 11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum